[s2If !current_user_can(access_s2member_level4)]This is premium content. You can get immediate access by becoming a valued Premium Member for India Portfolio. Click “Pay Now” and get access. Annual Membership Fee: Rs 20,000 only. (No other fee)
Access to company research of over 3900 publicly traded Indian companies.
Different Scoring of companies enabling quick decision to Buy, Sell, Hold, Avoid.
High quality portfolios of Indian companies
Excellent support
Access to private consultation via email and telegram
or you can visit India Membership page Login below to access company research.[lwa][/s2If] [s2If current_user_can(access_s2member_level4)]
Our Rating: HOLD
Mehabe score: 6 G Factor: 5 Piotski Score: 5 The stock has a rating HOLD. The mehabe team score is reflective of its fundamental and technical merits. A rating above 8 is considered good buy. The stock has a G-Factor of 5 and Piotski score of 5.
Description
Aspira Pathlab & Diagnostics is engaged in the business of running, owning, managing and administering Diagnostics Centers. The principal activities of the Company consist of pathology investigation services, radiology investigation services and other related healthcare services at Diagnostic Centres in Mumbai.Site:540788
Market Cap:
Rs 30.8 cr
Price:
29.9
Trading pe:
22.3x
Book-value:
8.07/share
Div yield:
0.00 %
Earning yield:
1.55%
Face-value:
10.0/share
52week high:
36.50
52week low:
20.00
Technical Analysis
Stock trades at 29.9, above its 50dma 25.73. It also trades above its 200dma 19.6. The stock remains bullish on techicals
The 52 week high is at 36.50 and the 52week low is at 20.00
Price Chart
P/E Chart
Sales and Margin
Strengths
– has reduced debt.
Weakness
– Stock is trading at 3.70 times its book value
-Promoter holding has decreased over last quarter: -3.90%
-Promoter holding is low: 36.25%
– has a low return on equity of -55.03% for last 3 years.
-‘s cost of borrowing seems high
Competition
– The industry trades at a mean P/E of 37.7x. Max Healthcare trades at the industry’s max P/E of 472.12x. 540788 trades at a P/E of 22.3x
– Industry’s mean G-Factor is 5.1 while the mean Piotski score is 9.0. 540788 has a G-Factor of 5 and Piotski scoreof 5.
– Average 1 month return for industry is 5.0%. The max 1- month return was given by Narayana Hrudaya: a return of 20.1 %
Quarterly Results
Sales for period ended Mar 2021 is Rs 4.12 cr compared to Rs 1.97 cr for period ended Mar 2020, a rise of 109.1%
Company reported operating profit of Rs 0.98 cr for period ended Mar 2021, operating profit margin at 23.8 %.
Operating profit was negative for the same period last year thus company has improved its margins this year
The EPS for Mar 2021 was Rs 0.42 compared to Rs 0.28 for previous quarter ended Dec 2020 and Rs -1.42 for Mar 2020
Profit & Loss Statement
Profit&Loss Comments
Company reported sales of Rs 15.21 cr for period ended Mar 2021 vis-vis sales of Rs 8.42 cr for the period ended Mar 2020, a healthy growth of 44.6%. The 3 year sales cagr stood at 51.7%.
Operating margins expanded to 23.14% for period ended Mar 2021 vis-vis -21.73% for period ended Mar 2020, expansion of 4487.0 bps.
Net Profit reported at Rs 1.38 cr for period ended Mar 2021 vis-vis sales of Rs -4.24 cr for the period ended Mar 2020, rising 0%.
Balance Sheet Statement
Cash Flow Statement
Cash Flow comments
CashFlow from operating activities: Rs 0.0 cr for period ended Mar 2021 vis-vis Rs -1.87 cr for period ended Mar 2020
Sales Growth
Profit Growth Statement
Profit Growth Statement
Stock Price CAGR
Return of Equity
General Comments
– The company has improved its Return on Equity (RoE) metric. The RoE on Last Year basis was 22.0% compared to -55.0% over the last 3 Years. – The stock has given a return of -22% on a 1 Year basis vis-vis a return of 19% over the last 3 Years. – The compounded sales growth on a TTM bassis is 81% vis-vis a compounded sales growth of 52% over the last 3 Years. – The compounded profit growth on a TTM basis is 133% vis-vis a compounded profit growth of 31% over the last 3 Years.
Ratios
Shareholding Pattern
– Public shareholding has risen for the period ended Mar 2021. The Mar 2021 public holding stood at 63.75% vis-vis 59.85% for Dec 2020
Conclusion
– has reduced debt. – Stock is trading at 3.70 times its book value
-Promoter holding has decreased over last quarter: -3.90%
-Promoter holding is low: 36.25%
– has a low return on equity of -55.03% for last 3 years.
-‘s cost of borrowing seems high
The business fundamentals of the stock remain stable. Stronger near term results will build interest in the stock. We suggest to wait for a upturn in business performance.
Technically, the stock remains above its 50 DMA 25.73 and is trading at 29.9, thus bullish price action wise.
